Should Stryker Buy Smith & Nephew?

Rumors earlier today that Stryker  was considering acquiring rival Smith & Nephew  were promptly shut down by Stryker management. The UK takeover laws now require a six month wait before Stryker could put in a bid for the company.

But would such a deal make sense if it were to go through?

There are a number of potential reasons to like such a deal -- some scale benefits by combining product lines, potential benefits stemming from a tax inversion, and the potential for Stryker to expand into new product areas.

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson lay out the case for why, if Stryker's management isn't planning to acquire Smith & Nephew, maybe they should think about it.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Should Stryker Buy Smith & Nephew? originally appeared on

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Intuitive Surgical and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story